What are the benefits of increasing cosentyx dosage?

What happens when patients increase Cosentyx dosage
Increasing the dose of Cosentyx (secukinumab) from 150 mg to 300 mg can improve skin clearance in people with moderate to severe plaque psoriasis. Clinical data show higher rates of PASI 90 and PASI 100 responses at the 300 mg dose, especially in heavier patients.

How does the higher dose affect psoriatic arthritis
For psoriatic arthritis, the 300 mg regimen provides stronger control of joint symptoms and enthesitis than the 150 mg dose. Patients on the higher dose report lower tender and swollen joint counts and better physical function scores after 16–24 weeks of treatment.

Who is most likely to need the 300 mg dose
The 300 mg dose is recommended for patients weighing more than 90 kg or those who show inadequate response to 150 mg after 16 weeks. Physicians often start at 150 mg and escalate only when disease activity remains high.

When does the dose increase take effect
Skin improvement after a dose increase can appear within 4–8 weeks, but full joint response may require up to 24 weeks. If no meaningful benefit is seen by week 16, guidelines advise reassessing the diagnosis or switching therapy.

Why do some patients stay on the lower dose
Many individuals achieve clear or almost clear skin on 150 mg, and the lower dose reduces injection frequency and cost. Staying at 150 mg is common when patients reach PASI 75 early and maintain that response.

Can the higher dose be used in other conditions
Cosentyx is approved at 300 mg for ankylosing spondylitis and non-radiographic axial spondyloarthritis. In these indications, the higher dose is standard from the start because lower doses showed inferior ASAS response rates in registration trials.

What side effects increase with higher dosing
Rates of nasopharyngitis, upper respiratory infections, and injection-site reactions rise slightly at 300 mg, but serious adverse events remain comparable to the 150 mg dose. Long-term safety data up to five years show no new signals tied to dose escalation.

How does insurance coverage change with dose escalation
Some plans require documented failure of 150 mg before approving 300 mg, which can delay access. Others cover the higher dose immediately for patients above 90 kg. Prior authorization forms often ask for body-weight documentation and prior treatment history.

When does Cosentyx patent protection end
U.S. composition-of-matter patents for secukinumab expire in 2026, with possible pediatric exclusivity extending protection to 2027. Biosimilar competition is expected shortly after these dates, which may affect pricing and access to both dose strengths.